Friday , 29 March 2024
Home » World » Cure for Hepatitis C Helps HIV Patients, Study
Cure for Hepatitis C Helps HIV Patients, Study
Cure for Hepatitis C Helps HIV Patients, Study

Cure for Hepatitis C Helps HIV Patients, Study

Gilead’s controversial Hepatitis C drug Sofosbuvir (brand name Sovaldi) is back in the news again, this time not over its cost, but for successfully clearing Hepatitis C in patients with HIV.

Hepatitis C is a contagious liver disease which can last anywhere from several weeks to a lifetime. Infection with HCV is often undiagnosed, with an estimated 50 percent of infected individuals who do not know it. Hepatitis C can lead to chronic liver disease, cirrhosis, and less frequently liver caner.

“Because of poor tolerability to the previous standard of treatments for Hepatitis C, co-infection patients were considered difficult to treat,” said Mark Sulkowski, medical director of the Johns Hopkins Infectious Disease Centre for Viral Hepatitis.

Now, the data from a Phase III clinical trial have been incorporated into the US Food and Drug Administration’s (FDA) approval of the new drug called sofosbuvir.

“The treatment with a new all-oral regimen – sofosbuvir and ribavirin – is now considered on-label,” researchers reported.

For the trial, doctors administered sofosbuvir and ribavirin to a total of 223 HIV-1 patients chronically co-infected with Hepatitis C either for 12 weeks.

Twelve weeks after the treatment ended, researchers tested patients again for Hepatitis C infection to determine if the treatment was effective.

They found that 76 percent patients with genotype 1, 88 percent with genotype 2 and 67 percent with genotype 3 were cured.

“We have always termed this to be ‘sustained virologic response but we now know that means hepatitis C has been cured,” Sulkowski noted.

The trial study was published in the Journal of the American Medical Association.

Agencies/Canadajournal




  • About News

    Web articles – via partners/network co-ordinators. This website and its contents are the exclusive property of ANGA Media Corporation . We appreciate your feedback and respond to every request. Please fill in the form or send us email to: [email protected]

    Leave a Reply